Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chi Leung Chiang"'
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Frontiers in Oncology
Frontiers in Oncology
Background: Current treatments of unresectable hepatocellular carcinoma (HCC) are trans-arterial chemo-embolization (TACE), stereotactic body radiotherapy (SBRT), and targeted therapy. However, these treatments are limited in efficacy and safety for
Autor:
Conrad Lee, Kwong Chuen Leung, Marc K. C. Chong, Steward Tung, Jacques Jolivet, Francis A. S. Lee, Maria Lai, Chi-Leung Chiang, Chloe Kwok, Philip W.K. Kwong, Steven Kin-Lok Siu, FY Cheung, Benny Zee
Publikováno v:
American Journal of Clinical Oncology. 39:609-613
Objectives This multicenter, randomized, open-label, phase II trial evaluated the efficacy and safety of AEG35156 in addition to sorafenib in patients with advanced hepatocellular carcinoma (HCC), as compared with sorafenib alone. Methods Eligible pa
Autor:
Jessica W.Y. Lai, Darren M.C. Poon, James C.H. Chow, Horace C.W. Choi, Wai Tong Ng, Tin‐Ching Chau, Kwok-Hung Au, Anthony H.P. Tam, Victor Ho-Fun Lee, Chi-Leung Chiang, Edwin C.Y. Wong, Anne W.M. Lee, Alice K.W. Cheung
Publikováno v:
HeadneckREFERENCES. 41(10)
Background This study evaluates the contemporary care for patients with locally recurrent nasopharyngeal carcinoma after failure of the primary course of intensity modulated radiotherapy. Methods Eligible patients were identified through the Hong Kon
Autor:
Victor Ho-Fun Lee, Tsz-Him So, Amy T.Y. Chang, Anne W.M. Lee, Chi-Leung Chiang, Ka-On Lam, Tai-Chung Lam, Cheuk-Wai Choi
Publikováno v:
Journal of oncology practice. 14(10)
Nasopharyngeal carcinoma of the undifferentiated histologic subtype is endemic and prevalent in southeast Asia. The dramatic improvement of treatment outcomes and overall prognosis during the past few decades has been attributed to advances in diseas
Publikováno v:
Annals of Oncology. 30:ix69
Background The treatment landscape of metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly over past few years. Following publications of several large-scale randomised controlled trials (RCTs) Abiraterone (AA) and Docetaxel (D
Autor:
Ka-On Lam, D.K.H. Tong, Horace C.W. Choi, A.W.I. Lo, Chi-Leung Chiang, Ho Issac, Btt Law, Simon Law, So Tsz Him, S.Y. Chan, Victor Ho-Fun Lee, W. Chan, Dora L.W. Kwong
Publikováno v:
Annals of Oncology. 28:iii2-iii3